Print
|
Close
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Active:
Yes
Cancer Type:
Prostate Cancer
Unknown Primary
NCT ID:
NCT04428788
Trial Phases:
Phase I
Protocol IDs:
CC-94676-PCA-001 (primary)
NCI-2020-13275
U1111-1251-9174
Eligibility:
18 Years and older, Male
Study Type:
Treatment
Study Sponsor:
Celgene
NCI Full Details:
http://clinicaltrials.gov/show/NCT04428788
Summary
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of
CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Treatment Sites in Georgia
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.